<DOC>
	<DOCNO>NCT00003602</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat old patient acute myeloid leukemia . PURPOSE : Randomized phase III trial compare effectiveness two different combination chemotherapy regimens treat old patient acute myeloid leukemia first remission .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy oral idarubicin etoposide vs intravenous mitoxantrone , etoposide , cytarabine consolidation therapy patient 55 year old acute myeloid leukemia first complete remission . - Compare toxicity 2 regimens patient . - Assess quality life patient . OUTLINE : This randomize study . Patients stratify accord number course induction therapy require achieve complete remission . All patient receive induction chemotherapy consist idarubicin IV day 1-3 cytarabine IV 12 hour day 1-7 . Patients receive 1-2 course induction chemotherapy achieve complete remission . Patients randomize one two treatment arm consolidation therapy achieve complete remission . - Arm I : Patients receive 2 course mitoxantrone IV day 1 2 , etoposide IV 1 hour day 1-5 , cytarabine IV 12 hour day 1-5 . - Arm II : Patients receive 2 course oral idarubicin etoposide day 1-3 . Quality life assess course consolidation chemotherapy 6-8 week completion therapy . Patients follow death . PROJECTED ACCRUAL : Approximately 400 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm de novo secondary acute myeloid leukemia ( AML ) Prior myelodysplasia allow Refractory anemia excess blast ( RAEB ) OR RAEB transformation No relapse AML No chronic granulocytic leukemia transformation No CNS disease PATIENT CHARACTERISTICS : Age : Over 55 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Transaminases great 2.5 time ULN Renal : Creatinine great 2.5 time ULN Cardiovascular : No severe uncontrolled cardiac failure Other : No serious medical , social , psychological condition Not HIV 1 2 seropositive PRIOR CONCURRENT THERAPY : Biologic therapy : No plan future autograft Chemotherapy : No prior chemotherapy myelodysplastic syndrome AML Endocrine therapy : Not specifed Radiotherapy : Not specify Surgery : Not specify Other : No concurrent aluminum magnesiumbased antacid</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>